AGEN

AGEN

USD

Agenus Inc. Common Stock

$3.980+0.140 (3.646%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$3.840

High

$3.980

Low

$3.700

Volume

0.33M

Company Fundamentals

Market Cap

126.8M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

0.46M

Exchange

NCM

Currency

USD

52-Week Range

Low $1.38Current $3.980High $7.34

Related News

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus with a Buy and maintains $23 price target.

View more
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target
BusinessWire

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Agenus Inc. (NASDAQ:AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite‑stable

View more
France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
Earnings Call Transcripts

Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)

Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)

View more
Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)
PR Newswire

FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone

Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with...

View more
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus with a Buy and maintains $23 price target.

View more
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target
BusinessWire

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Webcast details updated from the August 11th release Webcast on Wednesday, August 27, 2025 at 4:00 p.m. EST Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced an update to its